scholarly journals The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort

2020 ◽  
Vol 44 (3) ◽  
pp. 219-226
Author(s):  
Karinna Saxby ◽  
Carolyn Nickson ◽  
G. Bruce Mann ◽  
Louiza Velentzis ◽  
Hannah L. Bromley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Financial Impact

The financial impact of trastuzumab in metastatic breast cancer: The experience of the Institut Curie

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 663-663
Author(s):  
M. A. Doz ◽  
C. D. Le Tourneau ◽  
M. S. Guilhaume ◽  
V. Dieras ◽  
A. Vincent-Salomon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Single Agent ◽  
Metastatic Breast ◽  
Financial Impact ◽  
Her2 Overexpression ◽  
Breast Cancers ◽  
Financing System ◽  
High Level ◽  
The Cost

663 Purpose: To estimate, in term of public health on the scale of a region, the cost of trastuzumab and to point out the financial impact of this new targeted therapy in the adjuvant setting. Methods: To understand the consequences of the spending on of trastuzumab at a macroeconomic level in the French hospital financing system, we decided to focus on an establishment in particular, and to analyze the increasing spending of trastuzumab at a micro-economic level, to provide a cost analysis of patients treated with trastuzumab for HER2-overexpressing metastatic breast cancer. We retrospectively reviewed 137 medical reports of patients who received trastuzumab either in combination with chemotherapy or as a single agent and in maintenance therapy. Median age of the patients was 52 years (range 32- to 79+). Eighty five percent had 3+ HER2 overexpression and fifteen percent had 2+ HER2 (FISH amplified). Results: Median survival from first treatment with trastuzumab was 38.5 months (range 0,04–53,06+). The cost of the first year treatment is in average €43,435.58 per patient, for the second year €36,419.01 and for the third year €37,198.94. Drugs cost represents 78% of the hospital stays cost for a patient and 2.9% of the budget of Institut Curie. Conclusions: This retrospective analysis showed the very high level of expenses of trastuzumab to treat metastatic breast cancers. With the adjuvant use of trastuzumab, it is expected that these expenses are going to increase exponentially. No significant financial relationships to disclose.

Racial differences in the financial impact of breast cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18293-e18293
Author(s):  
Stephanie B. Wheeler ◽  
Jennifer Spencer ◽  
Laura C Pinheiro ◽  
Lisa A. Carey ◽  
Andrew F Olshan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Health Insurance ◽  
Black Women ◽  
Racial Differences ◽  
White Women ◽  
Large Population ◽  
Financial Impact ◽  
Barriers To Treatment ◽  
Financial Barriers ◽  
Transportation Barriers

e18293 Background: Racial variation in the adverse financial impact of cancer may contribute to observed differences in the initiation and completion of guideline-recommended adjuvant treatments. We describe racial differences in the financial impact of breast cancer diagnosis in a large, population-based, prospective cohort study. Methods: Patients were recruited via rapid case ascertainment through the North Carolina cancer registry as part of the Carolina Breast Cancer Study, with oversampling of black women and women younger than 50. Participants provided medical records and survey data on demographics, socioeconomic status, treatments, and financial impact of cancer. We used chi-square tests and multivariable logistic regression to understand racial differences in financial impact of breast cancer through 25 months post-diagnosis. Results: Our sample included 1,196 non-Hispanic blacks and 1,236 non-Hispanic whites. Since diagnosis, compared to white women, black women more often reported: any adverse financial impact of cancer (59% vs 39%, p < 0.0001); lost income (49% vs 35%, p < 0.0001); lost job due to cancer (13% vs 6%, p < 0.0001); financial barriers to treatment (24% vs 10%, p < 0.0001); transportation barriers to treatment (15% vs 3%, p < 0.0001); and lost health insurance (9% vs 3%, p < 0.0001). In multivariable models, black women had higher odds of: experiencing any adverse financial impact of cancer (Adjusted Odds Ratio [AOR]: 1.9 (1.6-2.3)); losing income (AOR: 1.5 (1.3-1.9)); losing their job (AOR: 2.1 (1.5-2.8)); experiencing financial barriers to treatment (AOR: 2.2 (1.7-2.9)); experiencing transportation barriers to treatment (AOR: 4.8 (3.2-7.1)); and losing their health insurance (AOR: 2.6 (1.7-4.1)). Conclusions: Compared to whites, black women with breast cancer experience significantly worse financial impact of cancer. Disproportionate financial strain may contribute to higher stress, lower treatment compliance, and worse outcomes, among black women. Efforts to alleviate the adverse financial impact of cancer treatment and to improve communication between patients and providers about potential financial distress may be particularly valuable for black women, due to their greater financial vulnerability.

Cancer-related financial burden among patients with metastatic breast cancer.

2018 ◽  
Vol 36 (30_suppl) ◽  
pp. 32-32 ◽  
Author(s):  
Stephanie B. Wheeler ◽  
Jennifer Spencer ◽  
Michelle L. Manning ◽  
Cleo A. Samuel ◽  
Katherine Elizabeth Reeder-Hayes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Health Insurance ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Financial Burden ◽  
Metastatic Breast ◽  
Financial Impact ◽  
Insurance Status ◽  
Breast Cancer Patients ◽  
Health Insurance Status

32 Background: Recent data suggest that the adverse financial impact of cancer is an underappreciated source of potential harm to patients, also known as “financial toxicity”. Little is known about the financial impact of cancer in patients with widespread, incurable disease, despite the relatively high cost of their care. We conducted a national survey of patients with metastatic breast cancer to address this gap. Methods: We partnered with the Metastatic Breast Cancer Network to field an online survey of metastatic breast cancer patients over a fourteen-day period using Qualtrics. The survey required approximately 20 minutes to complete, and participants were offered a $10 Amazon gift card. Survey items included sociodemographic information, health insurance status, cost-related communication with providers, post-treatment financial burden, financial coping strategies, and emotional well-being. We report financial outcomes stratified by health insurance status, as insurance is an important protective mechanism against health-related financial shocks. Results: 1,513 participants responded from 41 states. More than a third of these women (35%) were uninsured. Uninsured individuals more often reported refusing or delaying treatment due to cost (98% vs. 41% of insured, p < .001) and were also more likely to report skipping non-medical bills (40% vs. 16%, p < .001), stopping work after diagnosis (65% vs. 46%, p < .001), or being contacted by a collections agency (77% vs. 36%, p < .001). Despite this, insured participants reported higher cost-related emotional distress, including being “quite a bit” or “very” stressed about not knowing cancer costs (53% vs. 32%, p < .001) and about financial stress on their family due to their cancer (52% vs. 27%, p < .001). Conclusions: Metastatic breast cancer patients reported an unprecedented level of cancer-related financial harm and significant worry about the financial legacy left behind in the wake of their illness. Health insurance expansion is a necessary, but insufficient strategy to address this financial burden; additional interventions to prevent and mitigate cancer-related financial harm are urgently needed.

scholarly journals Breast cancer-related lymphedema and its treatment: how big is the financial impact?

2020 ◽  
Author(s):  
Tessa De Vrieze ◽  
Nick Gebruers ◽  
Ines Nevelsteen ◽  
Wiebren A. A. Tjalma ◽  
Sarah Thomis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Financial Impact ◽  
Breast Cancer Related Lymphedema
Sign in / Sign up

Export Citation Format

Share Document